Загрузка видео...

Не удалось загрузить видео

На главную

Can We Finally Reverse Aging? Dr. Aubrey de Grey explains a new breakthrough in longevity research using an engineered enzyme that repairs molecular damage once thought permanent. FULL STORY: Aubrey de Grey The LEV Foundation Revel Pharmaceuticals The Scientist #longevity #life #tech #research #aging

27,214 просмотров • 1 месяц назад •via X (Twitter)

Комментарии: 0

Нет доступных комментариев

Здесь появятся комментарии из оригинального поста

Похожие видео

Today’s guest on the Free Radicals podcast is Michael Ringel, JD PhD, COO Life Biosciences and former Managing Director at Boston Consulting Group. Michael is a leader in longevity and pharma who spent 25+ years advising top pharma companies on their R&D strategy. He is now COO at Life Biosciences where he is bringing the first ever partial epigenetic reprogramming therapy to human clinical trials - a major milestone for the longevity industry. In this episode, we discuss Michael’s insightful paper on why aging is an optimization by evolution, why that means it’s malleable, and how to push the longevity field forward. Michael also sits on the US board of Hevolution Foundation and on the board of the AFAR. Be sure to follow me and Eric Dai to stay up to date on the latest news in longevity biotech! 0:00 Intro 2:30 Why aging is an optimization by evolution 15:10 Why scientists miss the role of evolution in aging 19:31 Evidence that aging is a regulated process 24:40 Hormesis and adaptive stress responses 28:55 The promise of partial epigenetic reprogramming in humans 35:08 Life Bio's first therapy proceeding to clinical trials 47:47 Why targeting the eye, particularly glaucoma and NION, is a strategic choice 52:03 The pharma industry's perspective on anti-aging research 56:39 The importance of public engagement for funding and policy change 1:05:42 Reasons for optimism in longevity 1:08:26 Advice on how to have an impactful and interdisciplinary career 1:11:54 The ethical case for longevity 1:17:34 Concrete steps for audience members to support longevity research

Daniel Shur

16,988 просмотров • 5 месяцев назад

Friedberg: New study shows enzyme reverses skin age from 70+ years to 31 Chamath: That’s a $2T market. Did Scientists Just Discover How to Reverse Skin Aging!? “CML is kind of the predominant molecule that gets formed in this extracellular matrix that's driving aging, and nothing breaks it down. So these scientists set out to try and create an enzyme, an enzyme is a protein that breaks something down, that can break down CML. And so these guys kind of went out and they took the target, which is CML, and tried to figure out, ‘Okay, how do we actually degrade CML, clear that extracellular matrix, and reverse aging?’ They started to test it on the proteins that we would find in our body, casein, collagen, retinal proteins, which are in your eye, hemoglobin, and they were able to get rid of 52 to 97% of the CML, just degrade it away. And then they found several sites where they were able to degrade over 90%. And then they took actual human skin from elderly patients that had donated their skin, and they put this enzyme onto that skin, and they were able to eliminate 55% of the CML on the skin, basically reverse the skin's age down to the age of a 31-year-old, this is from greater than 70-year-old patients, just by putting this enzyme on the skin. And so it's kind of a groundbreaking demonstration of combination of AlphaFold, what's called directed evolution, where you change the order of the DNA that changes the structure of the protein to test different proteins, do high throughput screening, and ultimately make a novel protein that doesn't exist in nature today that can do something pretty profound for human health.” Chamath: “It will be a trillion-dollar market. If you can create a cream…” Friedberg: “I mean, dude, if you could put this enzyme literally on your skin and have it absorb in…” Chamath: “Game over. That alone is $2 trillion.”

The All-In Podcast

2,983,249 просмотров • 2 месяцев назад

$GOOGL has an anti-aging asset nobody is pricing. Friedberg david friedberg walked through a Calico paper that should be on Alphabet holders' radar. Calico is Google's longevity lab. Working with Revel Pharma, it used AlphaFold plus directed evolution to design a novel enzyme that degrades CML, the glycation end-product that stiffens tissue and drives aging. The result is not a slide. Across five recursive design cycles the enzyme degraded **52-97%** of CML on human proteins, and on donated skin from patients over 70 it eliminated about **55%** of CML - reversing the skin's profile toward that of a 31-year-old. It is AI-designed proteins doing something genuinely new in biology, not a benchmark score. Chamath Chamath Palihapitiya frames the first market as cosmetic: a workable anti-aging cream is a multi-trillion-dollar category. This is the AlphaFold thesis paying out in a product line, and the AlphaFold-to-drugs bridge is exactly what Demis Hassabis Demis Hassabis has argued is the real near-term return on Google's AI - not chatbots, but designed molecules. Same company, same stack, a second revenue engine the market files under "research." Implication: this is deep-optionality inside a name you already hold on search and cloud. It does not move the $GOOGL model this year. But it is a reminder that Alphabet's AI edge shows up in drug and materials design, an option the Street assigns roughly zero value. If a Calico or Isomorphic asset reaches a real market, that is upside no analyst is underwriting. Watch for Calico or Isomorphic Labs to move a designed molecule toward a commercial or clinical path.

Podcast Alpha

124,354 просмотров • 1 месяц назад